A B Dietz

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells
    Seiga Ohmine
    Department of Molecular Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Stem Cell Res Ther 2:46. 2011
  2. ncbi Vasoprotective effects of human CD34+ cells: towards clinical applications
    Thomas J Kiernan
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 7:66. 2009
  3. ncbi Maturation of human monocyte-derived dendritic cells studied by microarray hybridization
    A B Dietz
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Biochem Biophys Res Commun 275:731-8. 2000
  4. ncbi Infrastructure development for human cell therapy translation
    A B Dietz
    Human Cellular Therapy Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Pharmacol Ther 82:320-4. 2007
  5. ncbi A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers
    Allan B Dietz
    Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55095, USA
    Transfusion 46:2083-9. 2006
  6. ncbi Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
    Allan B Dietz
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:1094-9. 2004
  7. ncbi Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia
    A B Dietz
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Croat Med J 42:428-35. 2001
  8. ncbi Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone
    Michael P Gustafson
    Division of Transfusion Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Neuro Oncol 12:631-44. 2010
  9. ncbi Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML
    M R Litzow
    Division of Hematology and Department of Internal Medicine, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905, USA
    Cytotherapy 8:290-8. 2006
  10. ncbi Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression
    A B Dietz
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Rochester, MN, USA
    Gene Ther 8:419-23. 2001

Detail Information

Publications30

  1. ncbi Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells
    Seiga Ohmine
    Department of Molecular Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Stem Cell Res Ther 2:46. 2011
    ..One of the key issues for clinical-grade iPSC derivation is the accessibility of donor cells used for reprogramming...
  2. ncbi Vasoprotective effects of human CD34+ cells: towards clinical applications
    Thomas J Kiernan
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 7:66. 2009
    ..We used a novel immunodeficient rat carotid injury model in order to determine whether human cells could improve vascular remodelling following acute injury...
  3. ncbi Maturation of human monocyte-derived dendritic cells studied by microarray hybridization
    A B Dietz
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Biochem Biophys Res Commun 275:731-8. 2000
    ..Moreover, MDC transcribed and translated insulin like growth factor-1 receptor, transforming growth factor alpha, and neuropeptide Y...
  4. ncbi Infrastructure development for human cell therapy translation
    A B Dietz
    Human Cellular Therapy Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Pharmacol Ther 82:320-4. 2007
    ....
  5. ncbi A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers
    Allan B Dietz
    Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55095, USA
    Transfusion 46:2083-9. 2006
    ..Buffy coats are becoming less available as a source of research-grade peripheral blood mononuclear cells (PBMNCs). Therefore, alternative sources of these cells were investigated...
  6. ncbi Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
    Allan B Dietz
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:1094-9. 2004
    ..These findings indicate that long-term administration of high-dose imatinib mesylate might affect immunity...
  7. ncbi Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia
    A B Dietz
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Croat Med J 42:428-35. 2001
    ..As an example of the complexity in a clinical trial of dendritic cell vaccines, we present our ongoing trial in immunotherapy of chronic myelogenous leukemia...
  8. ncbi Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone
    Michael P Gustafson
    Division of Transfusion Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Neuro Oncol 12:631-44. 2010
    ..Consequently, we have developed a model for tumor mediated systemic immune suppression via recruitment and transformation of CD14(+) cells...
  9. ncbi Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML
    M R Litzow
    Division of Hematology and Department of Internal Medicine, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905, USA
    Cytotherapy 8:290-8. 2006
    ....
  10. ncbi Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression
    A B Dietz
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Rochester, MN, USA
    Gene Ther 8:419-23. 2001
    ..Expression of CD83 and p40 were unaffected by adenovirus infection and transferred gene expression. Thus, immature dendritic cells infected with recombinant adenoviruses can be matured when desired after transferred gene expression...
  11. ncbi Maturation of human dendritic cells as sulfasalazine target
    R Matasic
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Croat Med J 42:440-5. 2001
    ....
  12. ncbi Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous T(H)1 T cells
    A B Dietz
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Cytotherapy 3:97-105. 2001
    ..DISCUSSION: CML-DC can be modified genetically and functionally by recombinant replication-defective adenoviruses, providing new possibilities for clinical trials in dendritic cell-based immunotherapy...
  13. ncbi Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma
    A B Dietz
    Stem Cell Laboratory, Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Cytotherapy 6:563-70. 2004
    ..This robust and reproducible method provides cells of consistent phenotype and viability. Cryopreservation in single-dose aliquots allows multiple DC vaccine doses to be manufactured from a single apheresis product...
  14. ncbi In vivo sodium iodide symporter gene therapy of prostate cancer
    C Spitzweg
    Department of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA
    Gene Ther 8:1524-31. 2001
    ....
  15. ncbi Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer
    Stanimir Vuk-Pavlovic
    Stem Cell Laboratory, Mayo Clinic Cancer Center, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Prostate 70:443-55. 2010
    ..To determine if the levels of circulating myeloid-derived suppressor cells increase with progression of prostate cancer (PCa); to determine if such cells could contribute to the relative inefficiency of PCa immunotherapy...
  16. ncbi Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties
    Jennifer C Rodrigues
    Department of Neurologic Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Neuro Oncol 12:351-65. 2010
    ....
  17. ncbi Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks
    Jann N Sarkaria
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 16:5573-80. 2010
    ..The mammalian target of rapamycin (mTOR) functions within the phosphoinositide 3-kinase/Akt signaling pathway as a critical modulator of cell survival...
  18. ncbi A combined flow cytometry-based method for fetomaternal hemorrhage and maternal D
    Darcie J Radel
    Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Transfusion 48:1886-91. 2008
    ..We have enhanced this method by combining the fetomaternal bleed assay with a D antibody in the same tube to determine the maternal D as well as the need for Rh immune globulin (RhIG) administration...
  19. ncbi Immunomagnetic separation reagents as markers in electron microscopy
    Phyllis J Fisher
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First St, S W, Rochester, MN 55905, USA
    J Immunol Methods 262:95-101. 2002
    ..The large number of commercially available immunomagnetic reagents specific for different human, mouse and rat antigens provides additional resources for visualization of cellular ultrastructure...
  20. ncbi Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  21. ncbi Sterility testing of hematopoietic progenitor cell products: a single-institution series of culture-positive rates and successful infusion of culture-positive products
    Douglas J Padley
    Transfusion Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Transfusion 47:636-43. 2007
    ..Numerous studies have reported the infusion of culture-positive HPCs; however, the low frequency of adverse events prevents accurate determination of this risk...
  22. ncbi Carotid repair using autologous adipose-derived endothelial cells
    Harald Froehlich
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Stroke 40:1886-91. 2009
    ..To define whether delivery of adipose-derived endothelial cells (ADECs) would improve healing of injured carotid arteries, a rabbit model of acute arterial injury was used...
  23. ncbi Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells
    Ryan A Wilcox
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:2936-44. 2009
    ..Collectively, the data presented demonstrate a previously undescribed role for monocytes in T-cell lymphoproliferative disorders...
  24. ncbi Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies
    H T Ong
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Gene Ther 14:324-33. 2007
    ..In conclusion, virus-loaded T cells may facilitate systemic measles virotherapy in the presence of antiviral Abs and they warrant further investigation as potential MV cell carriers...
  25. ncbi Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model
    Ianko D Iankov
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res Treat 122:745-54. 2010
    ..This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer...
  26. ncbi Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression
    Wei Ding
    Division of Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 147:471-83. 2009
    ..These findings support a bi-directional activation between bone marrow stromal cells and CLL B-cells...
  27. ncbi Dendritic cell microvilli: a novel membrane structure associated with the multifocal synapse and T-cell clustering
    Phyllis J Fisher
    Mayo Clinic, Rochester, MN, USA
    Blood 112:5037-45. 2008
    ..T cells preferentially bound to this site in clusters often contained both CD4(+) and CD8(+) T cells...
  28. ncbi Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis
    Consuelo M López De Padilla
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Arthritis Rheum 56:1658-68. 2007
    ..To examine whether dendritic cells (DCs) are constituents of muscle inflammation in juvenile dermatomyositis (DM)...
  29. ncbi Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma
    Kah Whye Peng
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 84:401-7. 2009
    ..Thus, TAM are a universal stromal component of the plasmacytomas of myeloma patients and may offer a promising new target for therapeutic exploitation. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  30. ncbi Converting tumor-specific markers into reporters of oncolytic virus infection
    Ianko D Iankov
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Mol Ther 17:1395-403. 2009
    ..This is the first report of a gene therapy vector engineered to discriminate between infection in malignant and normal cells by molecular modification of a tumor-specific protein...